Cargando…

Resistance of Leishmania (Viannia) Panamensis to Meglumine Antimoniate or Miltefosine Modulates Neutrophil Effector Functions

Leishmania (Viannia) panamensis (L. (V.) p.) is the main causative agent of cutaneous leishmaniasis in Colombia and is usually treated with either meglumine antimoniate (MA) or miltefosine (MIL). In recent years, there has been increasing evidence of the emergence of drug-resistance against these co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Regli, Ivo B., Fernández, Olga Lucía, Martínez-Salazar, Berenice, Gómez, Maria Adelaida, Saravia, Nancy Gore, Tacchini-Cottier, Fabienne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6308327/ https://www.ncbi.nlm.nih.gov/pubmed/30622537 http://dx.doi.org/10.3389/fimmu.2018.03040

Ejemplares similares

Neutrophil Activation: Influence of Antimony Tolerant and Susceptible Clinical Strains of L. (V.) panamensis and Meglumine Antimoniate
por: Fernández, Olga Lucía, et al.
Publicado: (2021)

Immuno-pharmacokinetics of Meglumine Antimoniate in Patients With Cutaneous Leishmaniasis Caused by Leishmania (Viannia)
por: Gómez, María Adelaida, et al.
Publicado: (2020)

Miltefosine and Antimonial Drug Susceptibility of Leishmania Viannia Species and Populations in Regions of High Transmission in Colombia
por: Fernández, Olga Lucía, et al.
Publicado: (2014)

Cost-effectiveness of meglumine antimoniate versus miltefosine caregiver DOT for the treatment of pediatric cutaneous leishmaniasis
por: Berger, Brandon A., et al.
Publicado: (2017)

Cutaneous leishmaniasis caused by Leishmania (Viannia) panamensis in 2 travelers
por: Achtman, Jordan C., et al.
Publicado: (2016)

The genome of Leishmania panamensis: insights into genomics of the L. (Viannia) subgenus.
por: Llanes, Alejandro, et al.
Publicado: (2015)

Mitochondrial genomics of human pathogenic parasite Leishmania (Viannia) panamensis
por: Urrea, Daniel Alfonso, et al.
Publicado: (2019)

Evaluation of a Multilocus Sequence Typing (MLST) scheme for Leishmania (Viannia) braziliensis and Leishmania (Viannia) panamensis in Colombia
por: Herrera, Giovanny, et al.
Publicado: (2017)

Detection of Leishmania RNA Virus 1 in Leishmania (Viannia) panamensis Isolates, Panama
por: Gonzalez, Kadir, et al.
Publicado: (2023)

Correction: Miltefosine and Antimonial Drug Susceptibility of Leishmania Viannia Species and Populations in Regions of High Transmission in Colombia
Publicado: (2014)

Histopathological characteristics of cutaneous lesions caused by Leishmania Viannia panamensis in Panama
por: González, Kadir, et al.
Publicado: (2018)

Intraspecific Genomic Divergence and Minor Structural Variations in Leishmania (Viannia) panamensis
por: Patino, Luz H., et al.
Publicado: (2020)

Early Leukocyte Responses in Ex-Vivo Models of Healing and Non-Healing Human Leishmania (Viannia) panamensis Infections
por: Gomez, Maria Adelaida, et al.
Publicado: (2021)

Evaluation of a Possible Synergistic Effect of Meglumine Antimoniate with Paromomycin, Miltefosine or Allopurinol on in Vitro Susceptibility of Leishmania tropica Resistant Isolate
por: REZAEI RIABI, Tahereh, et al.
Publicado: (2013)

Survival Mechanisms Used by Some Leishmania Species to Escape Neutrophil Killing
por: Regli, Ivo B., et al.
Publicado: (2017)

Mitochondrial Proteomics of Antimony and Miltefosine Resistant Leishmania infantum
por: Vincent, Isabel M., et al.
Publicado: (2015)

In Vitro Sensitivity of Paired Leishmania (Viannia) braziliensis Samples Isolated before Meglumine Antimoniate Treatment and after Treatment Failure or Reactivation of Cutaneous Leishmaniasis
por: Baptista, Cibele, et al.
Publicado: (2015)

Genotypic profiles of Leishmania (Viannia) braziliensis strains from cutaneous leishmaniasis patients and their relationship with the response to meglumine antimoniate treatment: a pilot study
por: Gagini, Thalita, et al.
Publicado: (2017)

BODY WEIGHT AS A DETERMINANT OF CLINICAL EVOLUTION IN HAMSTERS (Mesocricetus auratus) INFECTED WITH Leishmania (Viannia) panamensis
por: Gómez-Galindo, Ángela María, et al.
Publicado: (2013)

Insights into the Genetic Diversity of Leishmania (Viannia) panamensis in Panama, Inferred via Multilocus Sequence Typing (MLST)
por: Mendieta, Daniel, et al.
Publicado: (2023)

Human Macrophage Response to L. (Viannia) panamensis: Microarray Evidence for an Early Inflammatory Response
por: Ramírez, Carolina, et al.
Publicado: (2012)

Pharmacometabolomics of Meglumine Antimoniate in Patients With Cutaneous Leishmaniasis
por: Vargas, Deninson Alejandro, et al.
Publicado: (2019)

Involvement of the Inflammasome and Th17 Cells in Skin Lesions of Human Cutaneous Leishmaniasis Caused by Leishmania (Viannia) panamensis
por: Gonzalez, K., et al.
Publicado: (2020)

A Mouse Model of Ulcerative Cutaneous Leishmaniasis by Leishmania (Viannia) panamensis to Investigate Infection, Pathogenesis, Immunity, and Therapeutics
por: Muñoz-Durango, Natalia, et al.
Publicado: (2022)

Meglumine Antimoniate and Miltefosine Combined With Allopurinol Sustain Pro-inflammatory Immune Environments During Canine Leishmaniosis Treatment
por: Santos, Marcos Ferreira, et al.
Publicado: (2019)

Low doses of 3-phenyl-lawsone or meglumine antimoniate delivery by tattooing route are successful in reducing parasite load in cutaneous lesions of Leishmania (Viannia) braziliensis-infected hamsters
por: Meira, Rafaella de Miranda Villarim, et al.
Publicado: (2023)

Long-term follow-up of dogs with leishmaniosis treated with meglumine antimoniate plus allopurinol versus miltefosine plus allopurinol
por: Manna, Laura, et al.
Publicado: (2015)

Risk factors for therapeutic failure to meglumine antimoniate and miltefosine in adults and children with cutaneous leishmaniasis in Colombia: A cohort study
por: Castro, Maria del Mar, et al.
Publicado: (2017)

Biodistribution of meglumine antimoniate in healthy and Leishmania (Leishmania) infantum chagasi-infected BALB/c mice
por: Borborema, Samanta Etel Treiger, et al.
Publicado: (2013)

CD4 T cell activation by B cells in human Leishmania (Viannia) infection
por: Rodriguez-Pinto, Daniel, et al.
Publicado: (2014)

Serine proteases profiles of Leishmania (Viannia) braziliensis clinical isolates with distinct susceptibilities to antimony
por: Zabala-Peñafiel, Anabel, et al.
Publicado: (2021)

Pharmacokinetics of neutron-irradiated meglumine antimoniate in Leishmania amazonensis-infected BALB/c mice
por: Borborema, Samanta Etel Treiger, et al.
Publicado: (2019)

A Novel Strategy for Enhance Potentiation of Meglumine antimoniate against Leishmania major In Vitro
por: MIRZAEI, Farzaneh, et al.
Publicado: (2019)

AgNP-PVP-meglumine antimoniate nanocomposite reduces Leishmania amazonensis infection in macrophages
por: Gélvez, Ana Patricia Cacua, et al.
Publicado: (2021)

FIRST REPORT ON OTOTOXICITY OF MEGLUMINE ANTIMONIATE
por: Valete-Rosalino, Cláudia Maria, et al.
Publicado: (2014)

Inductively coupled plasma mass spectrometry method for plasma and intracellular antimony quantification applied to pharmacokinetics of meglumine antimoniate
por: Garay-Baquero, Diana J, et al.
Publicado: (2021)

Resistance of Leishmania (Viannia) braziliensis to nitric oxide: correlation with antimony therapy and TNF-α production
por: Souza, Anselmo S, et al.
Publicado: (2010)

Antileishmanial potentials of azacitidine and along with meglumine antimoniate on Leishmania major: In silico prediction and in vitro analysis
por: Derakhshani, Ali, et al.
Publicado: (2023)

The Impact of Neutrophil Recruitment to the Skin on the Pathology Induced by Leishmania Infection
por: Passelli, Katiuska, et al.
Publicado: (2021)

Comparative genomic analysis of Leishmania (Viannia) peruviana and Leishmania (Viannia) braziliensis
por: Valdivia, Hugo O., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_fhcqnndbdmqo8smtjap612suuv